Skip to main content
SpringerLink
Log in

Antiprogestin-progesterone interactions

  • Chapter
Mammary Tumor Cell Cycle, Differentiation, and Metastasis

Part of the book series: Cancer Treatment and Research ((CTAR,volume 83))

Abstract

It was more than a decade ago that in 1889 Schinzinger was the first to propose that ovariectomy may be an effective treatment for breast cancer [1,2]. Until today the available treatment strategies for hormone-dependent breast cancer have mainly been based on estrogen-ablative principles, and improvements in the therapy for breast cancer are still sorely needed. A totally different strategy utilizes progesterone antagonists: This class of compounds targets the progesterone receptor in mammary carcinomas and therefore does not represent another enzyme or receptor blockade of estrogen action.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schinzinger F (1889) Über Carcinoma Mammae. In Verh Dtsch Ges Chirurgie. Berlin: Hirschwald Verlag, Chap 18.

    Google Scholar 

  2. Beatson GT, Edin MD (1896) On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 18: 107–108.

    Google Scholar 

  3. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE (1982) The effects of an antiprogesterone steroid in women: Interruption of the menstrual cycle and of early pregnancy. C R Acad Sci Paris 294: 933–938.

    CAS  Google Scholar 

  4. Kloosterboer HJ, Deckers GHJ, Van der Heuvel MJ, Loozen HJJ (1988) Screening of antiprogestagens by receptor studies and bioassays. J Steroid Biochem 31: 567–571.

    Article  PubMed  CAS  Google Scholar 

  5. Beaulieu EE (1993) RU486 - a decade on, today and tomorrow. In Clinical Applications of Mifepristone RU486 and Other Antiprogestins. MS Donaldson, L Dorflinger, SS Brown, LZ Benet (eds). Washington, DC: National Academy Press, pp 71–119.

    Google Scholar 

  6. Philibert D (1985) Pharmacological profile of RU 486 in animals. In The Antiprogestin Steroid RU 486 in Human Fertility Control. EE Baulieu, SJ Segall (eds). New York: Plenum Press, pp 49–68.

    Google Scholar 

  7. Klijn JGM, de Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Aliexa-Figusch J (1989) Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49: 2851–2856.

    PubMed  CAS  Google Scholar 

  8. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aguillaume J, Baulieu EE (1992) Medical termination of early pregnancy with RU486 (mifepristone) followed by a prostaglandin analogue: Study in 16,369 women. Scand J Obstet Gynecol 71: 278–283.

    Article  CAS  Google Scholar 

  9. Teutsch G, Belanger A (1979) Regional and stereospecific synthesis of 11ß-substituted 19-nor-steroids. Tetrahedron Lett V17: 2051–2054.

    Article  Google Scholar 

  10. Bigsby RM, Young PCM (1992) Estrogen-like effects of the antiprogestin ZK 98.299. In Proceedings of the 74th Annual Meeting of the Endocrine Society, San Antonio, Texas, June 24–27, 1992. San Antonio, Endocrine Society, p 233.

    Google Scholar 

  11. Gronemeyer H, Benhamou B, Berry M, Bocquel MT, Gofflo D, Garcia T, Leronge T, Metzger D, Meyer ME, Tora L, Vergezac A, Chambon D (1992) Mechanism of antihormone action. J Steroid Biochem Mol Biol 41: 217–221.

    Article  PubMed  CAS  Google Scholar 

  12. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB (1992) Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: Analysis with zinc finger mutants and the progesterone antagonist ZK 98299. Proc Natl Acad Sci USA 98: 3050–3054.

    Article  Google Scholar 

  13. Delabre K, Guiochon-Mantel A, Milgrom E (1993) In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90: 4421–425.

    Article  PubMed  CAS  Google Scholar 

  14. Horwitz KB, Takimoto GS, Tung L (1994) When steroid antagonists act like agonists: Issues of hormone resistance and tissue specificity. In Program and abstracts, Dallas, IX International Congress on Hormonal Steroids, September 1994, Dallas, Texas.

    Google Scholar 

  15. Bardon S, Vignon F, Chalbos D, Rochefort H (1985) RU 486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via progesterone receptor. J Clin Endocrinol Metab 60: 692.

    Article  PubMed  CAS  Google Scholar 

  16. Horwitz KB (1985) The antiprogestin RU 38486: Receptor mediated progestin versus antiprogestin actions screened in estrogen-sensitive T 47 D10 human breast cancer cells. Endocrinology 116: 2236–2245.

    Article  PubMed  CAS  Google Scholar 

  17. Bardon S, Vignon F, Montcourrier P, Rochefort H (1987) Steroid receptor-mediated cytotoxity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441–1448.

    PubMed  CAS  Google Scholar 

  18. Gill P, Vignon F, Bardon S, Derocq S, Rochefort H (1987) Difference between R 5020 and the antiprogestin RU 486 on anti-proliferative effects on human breast cancer cells. Breast Cancer Res Treat 10: 37–45.

    Article  PubMed  CAS  Google Scholar 

  19. Terakawa N, Shimizu I, Tanizawa O, Matsumoto K (1988) RU 486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. J Steroid Biochem 31: 161–166.

    Article  PubMed  CAS  Google Scholar 

  20. Van den Berg HW, Martin JHJ, Lynch M (1990) Progestin/anti-progestin action towards human breast cancer cell lines differing in their progesterone receptor content. Br J Pharmacol 101(Suppl).

    Google Scholar 

  21. Thomas M, Monet JD (1992) Combined effects of RU 486 and Tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75: 865–870.

    Article  PubMed  CAS  Google Scholar 

  22. Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W (1993) Effect of Onapristone and medroxy-progesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 45: 315–319.

    Article  PubMed  CAS  Google Scholar 

  23. Van den Berg HW, Lynch M, Martin JHJ (1993) The relationship between affinity progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: Modulation via the glucocorticoid receptor. Eur J Cancer 29A: 1771–1775.

    PubMed  Google Scholar 

  24. Maass N, Eidmann H, Arps H, Jonat W (1994) Progesterone antagonist ZK 98.299 (Onapristone) inhibits growth of the estrogen receptor (ER) and progesterone receptor (PR) positive breast cancer cell line MCF-7. Tumordiagn Ther 15: 6–11.

    Google Scholar 

  25. Bowden TR, Hissom JR, Moore MR (1989) Growth stimulation of T47D human breast cancer cells by the antiprogestin RU 486. Endocrinology 124: 2642–2646.

    Article  PubMed  CAS  Google Scholar 

  26. Jeng MH, Jordan VC (1992) Estrogenic actions of RU 486 in estrogen responsive human breast cancer MCF-7 cells. Proc Am Assoc Cancer Res 282, abstr 1684.

    Google Scholar 

  27. Jeng M-H, Langan-Fahey SM, Jordan VC (1993) Estrogenic actions of RU 486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132: 2622–2630.

    Article  PubMed  CAS  Google Scholar 

  28. Meei-Huey J, Langan-Fahey SM, Jordan VC (1993) Estrogenic actions of RU 486 in hormone responsive MCF-7 human breast cancer cells. Endocrinology 132: 2622–2630.

    Article  Google Scholar 

  29. Herman M, Bhakta A, Underwood B, Kodali S, Moudgil VK (1993) Interaction of progesterone receptor from T47D human breast cancer cells with different progestins and antiprogestins. Abstract book, Endocrine Society, Las Vegas, abstract 957, p 290.

    Google Scholar 

  30. Lu J, Matsumoto K, Nishizawa Y, Tanaka A, Hirose T, Sato B (1991) Nonclassical androgen actions of RU 38.486 in androgen-responsive Shionogi carcinoma 115 cells in serum-free culture. J Steroid Biochem Mol Biol 39: 329–335.

    Article  PubMed  CAS  Google Scholar 

  31. Kloosterboer HJ, Deckers GHV, Van der Heuvel MJ, Loozen HJJ (1988) Screening of anti-progestagens by receptor studies and bioassays. J Steroid Biochem 31: 567–571.

    Article  PubMed  CAS  Google Scholar 

  32. Mizutani T, Bhakta A, Kloosterboer HJ, Moudgil VK (1992) Novel anti-progestins Org 31806 and Org 31710 interaction with mammalian progesterone receptor and DNA binding of anti-steroid receptor complexes. J Steroid Mol Biol 42: 695–704.

    Article  CAS  Google Scholar 

  33. Michna H, Nishino Y, Schneider MR, Louton T, El Etreby MF (1991) A bioassay for the evaluation of antiproliferative potencies of progesterone antagonists. J Steroid Biochem Mol Biol 38: 359–365.

    Article  PubMed  CAS  Google Scholar 

  34. Bargmann W, Fleischhauer K, Knopp A (1960) Über die Morphologie der Milchsekretion. II. Z Zellforsch 53: 545–568.

    Google Scholar 

  35. Bargmann W, Welsch W (1969) On the ultrastructure of the mammary gland. In Lactogenes. M Reynolds, SJ Folley (eds). Philadelphia: University of Pennsylvania Press, pp 43–52.

    Google Scholar 

  36. Haslam SZ, Shyalama G (1981) Relative distribution of estrogen and progesterone receptors among the epithelial, adipose, and connective tissue components of the normal mammary gland. Endocrinology 108: 825–830.

    Article  PubMed  CAS  Google Scholar 

  37. Russo H, Russo JH (1987) Development of the human mammary gland. In The Mammary Gland. MC Neville, CW Daniel (eds). New York: Plenum, pp 53–68.

    Google Scholar 

  38. Haslam SZ (1988) Progesterone effects on deoxyribonucleic acid synthesis in normal mousse mammary glands. Endocrinology 122: 464–470.

    Article  PubMed  CAS  Google Scholar 

  39. Russo IH, Medado J, Russo J (1989) Endocrine influences on the mammary glands. In Integument and Mammary Glands. TC Jones, U Mohr, RD Hunt (eds). Berlin: Springer Verlag, pp 252–266.

    Google Scholar 

  40. Neumann U, Mendoza A, Kühnel W, Nishino Y, Michna H (1996) A new assay for progestins. J Steroid Biochem Mol Biol, in press.

    Google Scholar 

  41. Michna H, Schneider MR, Nishino Y, El Etreby MF (1989) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34: 447–453.

    Article  PubMed  CAS  Google Scholar 

  42. Schneider MR, Michna H, Nishino Y, El Etreby MF (1989) Antitumor activity of the progesterone antagonists ZK 98299 and RU486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and MNU-induced mammary tumor model of the rat. Eur J Cancer Clin Oncol 25: 691–701.

    Article  PubMed  CAS  Google Scholar 

  43. Michna H, Schneider MR, Nishino Y, El Etreby MF, McGuire WL (1990) Progesterone antagonists block the growth of experimental mammary tumors in G0V1 Breast Cancer Res Treat 17: 155–156.

    Article  PubMed  CAS  Google Scholar 

  44. Bakker GH, Setyono-Han B, Portengen H, de Jong FH, Foekens JA, Klijn JGM (1990) Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 789–794.

    Article  PubMed  CAS  Google Scholar 

  45. Bakker GH, Setyono-Han B, de Jong FH, Klijn JGM (1987) Mifepristone in treatment of experimental breast cancer in rats. In Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti-) Steroidal Agents. JGM Klijn, R Paridaens, JA Foekens (eds). New York: Raven, pp 39–48.

    Google Scholar 

  46. Orlemans EOM, Deckers GH, Schoonen WGEJ, Kloosterboer HJ (1994) Pharmacology of the very selective antiprogestin Org 31710 and comparison with the antiprogesttins RU38486 and ZK 98299. Program and abstracts, Dallas TX, International Congress on Hormonal Steroids, p 81.

    Google Scholar 

  47. Michna H, Schneider MR, Nishino Y, El Etreby MF (1989) Antitumor activity of the antiprogesterones ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: Mechanistic studies. Breast Cancer Res Treat 14: 275–288.

    Article  PubMed  CAS  Google Scholar 

  48. Michna H, Nishino Y, Schneider MR (1993) Effective sequential treatment of experimental mammary carcinomas with Tamoxifen and the progesterone antagonist Onapristone. Proc Am Associ Cancer Res 34: 25.

    Google Scholar 

  49. Rumpel E, Michna H, Kühnel W (1993) Morphology of the rat uterus after long-term treatment with progesterone antagonists. Ann Anat 175: 141–149.

    PubMed  CAS  Google Scholar 

  50. Michna H, Nishino Y, Hasan SH, Schneider MR (1993) Morphological and endocrine reactions of hormone dependent target organs to a progesterone receptor blockade by a progesterone antagonist. Ann Anat 175: 303.

    Google Scholar 

  51. Nishino Y, Michna H, Hasan SH, Schneider MR (1991) The progesterone antagonist Onapristone modulates estrogen-dependent functions in different target organs in rats and mice. Acta Endocrinol 124(Suppl 1): 160.

    Google Scholar 

  52. Nishino Y, Michna H, Hasan SH, Schneider MR (1992) Involvement of the adrenal gland in the prolactin rise induced in the femal rat to an antiprogestin, Onapristone./Steroid Biochem Mol Biol 41: 841–845.

    CAS  Google Scholar 

  53. Koering MJ, Healy DL, Hodgen GD (1986) Morphologic response of endometrium to a progesterone receptor antagonist, RU 486, in monkeys. Fertil Steril 45: 280–287.

    PubMed  CAS  Google Scholar 

  54. Wolf JP, Hsiu JG, Anderson TL, Ulman A, Baulieu EE, Hodgen GD (1989) Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys. Fertil Steril 52: 1055–1060.

    PubMed  CAS  Google Scholar 

  55. Bigsby RM, Young PCM (1994) Estrogenic effects of the antiprogestin Onapristone in the rodent uterus. Am J Obstet Gynecol 171: 188–194.

    PubMed  CAS  Google Scholar 

  56. Tachi C, Tachi S, Lindner HR (1972) Modification by progesterone of oestradiol-induced cell proliferation, RNA synthesis and oestradiol distribution in the rat uterus. J Reprod Fertil 31: 59–76.

    Article  PubMed  CAS  Google Scholar 

  57. Clark BF (1973) The effect of estrogen and progesterone on uterine cell division and epithelial morphology in spayed-hypophysectomized rats. J Endocrinol 56: 341–342.

    Article  PubMed  CAS  Google Scholar 

  58. Martin L, Finn CA, Tinder G (1973) Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: An autoradiographic study. J Endocrinol 56: 133–144.

    Article  PubMed  CAS  Google Scholar 

  59. Bigsby RM, Cunha GR (1985) Effects of progestins and glucocorticoids on deoxyribonucleic acid synthesis in the uterus of the neonatal mouse. Endocrinology 117: 2520–2526.

    Article  PubMed  CAS  Google Scholar 

  60. Van der Schoot P, Bakker GH, Klijn JGM (1987) Effects of the progesterone antagonist RU 486 (mifepristone) on ovarian activity in the rat. Endocrinology 121: 1375–1382.

    Article  PubMed  Google Scholar 

  61. Bigsby RM, Cunha GR (1988) Progesterone and dexamethasone inhibition of uterine epithelial proliferation in two models of estrogen-independent growth. Am J Obstet Gynecol 518: 646–650.

    Google Scholar 

  62. Van der Schoot P, Uilenbroek JT, Slappendel EJ (1990) Effect of the progesterone antagonist mifepristone on the hypothalamo-hypophysial-ovarian axis in rats. J Endocrinol 124: 425–432.

    Article  PubMed  Google Scholar 

  63. Jo T, Terada N, Saji F, Tanizawa O (1993) Inhibitory effects of estrogen, progesterone, androgen and glucocorticoid on death of neonatal mouse uterine epithelial cells induced to proliferate by estrogen. J Steroid Biochem Mol Biol 46: 25–32.

    Article  PubMed  CAS  Google Scholar 

  64. Rauch M, Loosfeld H, Philibert D, Milgrom E (1985) Mechanism of action of an antiprogesterone, RU 468, in the rabbit endometrium. Effects of RU 468 on the progesterone receptor and on the expression of the uteroglobin gene. Eur J Biochem 148: 213–18.

    Article  PubMed  CAS  Google Scholar 

  65. Van Uem JFHM, Hsiu JG, Chillik CF (1989) Contraceptive potential of RU 486 by ovulation inhibition. I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation. Contraception 40: 171–184.

    Article  PubMed  Google Scholar 

  66. Neulen J, Williams RF, Hodgen GD (1990) RU 486: Induction of dose dependent elevations of estradiol receptor in endometrium from ovariectomized monkeys. J Clin Endocrinol Metab 71: 1074–1075.

    Article  PubMed  CAS  Google Scholar 

  67. Chwalisz K, Hegele-Hartung C, Fritzemeier KH, Beier HM, Elger W (1991) Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen Onapristone in rabbits: Relationship to uterine estrogen receptors. Endocrinology 129: 312–322.

    Article  PubMed  CAS  Google Scholar 

  68. Slayden OD, Brenner RM (1994) RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatto). J Clin Endocrinol Metab 78: 440–448.

    Article  PubMed  CAS  Google Scholar 

  69. Slayden OD, Hirst JJ, Brenner RM (1993) Estrogen action in the reproductive tract of rhesus monkeys during antiprogestin treatment. Endocrinology 132: 1845–1856.

    Article  PubMed  CAS  Google Scholar 

  70. Gottardis MM, Jordan VC (1988) Development of tamoxlfen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187.

    PubMed  Google Scholar 

  71. Reddel RR, Sutherland RL (1984) Tamoxifen stimulation of human breast cancer proliferation in vitro: A possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 20: 1419–1424.

    Article  PubMed  Google Scholar 

  72. Martin L (1981) Effects of antiestrogens on cell proferation in the rodent reproductive tract. In Non-steroidal Antioestrogens. Molecular Pharmacology and Antitumor Activity. RL Sutherland, VC Jordan (eds). New York: Academic Press, pp 47–55.

    Google Scholar 

  73. Howell A, Dodwell D, Laidlaw J, Anderson H, Anderson E (1990) Tamoxifen as an agonist for metastatic breast cancer. In Endocrine Therapy of Breast Cancer IV. A Goldhirsch (eds). Berlin: Springer Verlag, pp 49–58.

    Google Scholar 

  74. Osborne C (1993) Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47: 83–90.

    Article  PubMed  CAS  Google Scholar 

  75. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P, Laatikainen T (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660–664.

    PubMed  Google Scholar 

  76. Wakeling AE, Bowler J (1987) Steroidal pure antiestrogens. J Endocrinol 112: R7–10.

    Article  PubMed  Google Scholar 

  77. Brunne N, Bronzert D, Vindelov L, Rygaard K, Spang-Thomsen M, Lippman ME (1989) Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49: 1515–1520.

    PubMed  Google Scholar 

  78. Lamberts SWJ, Koper JW, de Jong FH (1991) The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 73: 187–191.

    Article  PubMed  Google Scholar 

  79. Jordan VC (1992) The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer 16: 134–176.

    Article  Google Scholar 

  80. Wakeling AE, Bowler J (1988) Biology and mode of action of pure antiestrogens. J Steroid Biochem 30: 141–149.

    Article  PubMed  Google Scholar 

  81. Stöckemann K, Chwalisz K (1993) Effects of the new progesterone antagonist ZK 136799 on surgically-induced endometriosis. Program of the 40th Annual Meeting of Obstetrics, Toronto, abstract.

    Google Scholar 

  82. Stöckemann K, Chwalisz K (1993) Effects of the progesterone antagonist Onapristone and ZK 136799 on surgically-induced endometriosis in rats. Program of the 37th Symposium of the German Endocrine Society Berlin, abstract.

    Google Scholar 

  83. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SS (1991) Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertil Steril 56: 402–407.

    PubMed  CAS  Google Scholar 

  84. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU486. J Clin Endocrinol Metab 76: 513–517.

    Article  PubMed  Google Scholar 

  85. McDonnell DP, Goldman ME (1994) RU 486 exerts antiestrogenic activities through a novel progesterone receptor A-form mediated mechanism. J Biol Chem 269: 1945–1949.

    Google Scholar 

  86. Tora A, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P (1989) The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 49: 1981–1986.

    Google Scholar 

  87. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU (1986) An estrogen-responsive element derived from the 5’ flanking region of the Xenopus vitellogenin A2 gene functions in trans-fected human cells. Cell 46: 1053–1061.

    Article  PubMed  Google Scholar 

  88. Döhler KD, Wuttke W (1975) Changes with age in levels of serum gonadotropins, prolactin, and gonadal steroids in prepubertal male and female rats. Acta Endocrinol 97: 898–916.

    Google Scholar 

  89. Horwitz KB, McGuire WL (1977) Progesterone and progesterone receptors in experimental breast cancer. Cancer Res 37: 1733–1738.

    PubMed  Google Scholar 

  90. Vollmer G, Michna H, Ebert K, Knuppen R (1992) Downregulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors. Cancer Res 52: 4642–4648.

    PubMed  Google Scholar 

  91. Gehring S, Michna H, Kühnel W, Nishino Y, Schneider MR (1991) Morphometrical and histochemical studies on the differentiation potential of progesterone antagonists in experimental mammary carcinomas. Acta Endocrinol 124: 177.

    Google Scholar 

  92. Tenniswood M, Michna H (1995) Apoptosis in Hormone-Dependent Cancers. Berlin: Springer Verlag.

    Google Scholar 

  93. Knabbe C, Lippmann ME, Flanders KC, Kasid A, Derynyck R, Dickson RB (1987) Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428.

    Article  Google Scholar 

  94. Bursch W, Grasl-Kraupp B, Ellinger A, Török L, Kienzl H, Miillauer L, Schufte-Hermann R (1995) Active cell death and cancer. In M Tenniswood, H Michna (eds). Apoptosis in Hormone Dependent Cancers. Berlin: Springer Verlag, pp 83–103.

    Google Scholar 

  95. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB, Baum M (1992) Anti-estrogens induce the secretion of active transforming growth factor-beta from fetal fibroblasts. Br J Cancer 62: 405–409.

    Google Scholar 

  96. Scott RE, Hoerl BJ, Wille JJ, Florine DL, Krawisz BR, Kankatsu Y (1982) Coupling of proadipocyte growth arrest and differentiation. IL A cell cycle model for the physiological control of cell proliferation. J Cell Biol 94: 400–405.

    Article  PubMed  Google Scholar 

  97. Wille JJ, Maercklein PB, Scott RE (1982) Neoplastic transformation and defective control of cell proliferation and differentiation. Cancer Res 42: 5139–5146.

    PubMed  Google Scholar 

  98. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633.

    Article  PubMed  Google Scholar 

  99. McGuire WL, Dressler LG (1985) Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst 75: 405–410.

    PubMed  Google Scholar 

Download references

Authors
  1. H. Michna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.-H. Fritzemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Parczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. R. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Cell Biology and Pharmacology, Lombardi Cancer Center, The Research Building, 3970 Reservoir Road, 20007, Washington, DC, USA

    Robert B. Dickson PHD

  2. Departments of Medicine and Pharmacology, Lombardi Cancer Center, The Research Building, 20007, 3970 Reservoir Road, Washington, CD, USA

    Marc E. Lippman MD

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Michna, H., Fritzemeier, KH., Parczyk, K., Nishino, Y., Schneider, M.R. (1996). Antiprogestin-progesterone interactions. In: Dickson, R.B., Lippman, M.E. (eds) Mammary Tumor Cell Cycle, Differentiation, and Metastasis. Cancer Treatment and Research, vol 83. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1259-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1259-8_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8536-6

  • Online ISBN: 978-1-4613-1259-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation